With the integrated ADME-Tox capabilities, we support the project in the hit-to-lead, lead optimization, and preclinical development phase. The tailorable services are widely spread over the whole nonclinical ADME-Tox area: in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions, pharmacokinetics on different rodent species, and quantitative bioanalysis.
With an eye on the regulatory requirements for successful IND application, we integrate ADME readouts into the drug discovery process to ensure:
- To only advance drugs with a favorable pharmacological profile.
- Hone the drug candidates early in the process to ensure high bioavailability in the organism.
- Determine drug-drug interactions, in vitro toxicity, and inhibition of metabolic enzymes to ensure low side effects.